iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,580.00
+20.00 (0.56%)
Dec 10, 2025, 3:30 PM KST
-19.73%
Market Cap113.18B
Revenue (ttm)5.56B
Net Income (ttm)-6.29B
Shares Out31.61M
EPS (ttm)-197.47
PE Ration/a
Forward PEn/a
Dividend100.00 (2.79%)
Ex-Dividend DateDec 29, 2025
Volume90,638
Average Volume162,172
Open3,550.00
Previous Close3,580.00
Day's Range3,500.00 - 3,695.00
52-Week Range3,135.00 - 6,060.00
Beta0.53
RSI44.69
Earnings DateNov 28, 2025

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 71
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2024, iNtRON Biotechnology's revenue was 6.42 billion, a decrease of -33.05% compared to the previous year's 9.59 billion. Losses were -2.59 billion, -73.27% less than in 2023.

Financial Statements

News

There is no news available yet.